Morning Movers
Watch us on YouTube Live at 8:30AM EST

TSLA.NQ -1.87%
Tesla – Beat Wall Street expectations for first-quarter revenue recording record deliveries for the three-month period on robust demand from China. The company had said it delivered a record 184,800 vehicles globally in the January to March quarter, beating market expectations. The carmaker, led by billionaire entrepreneur Elon Musk, said revenue rose to $10.39 billion from $5.99 billion a year earlier. Analysts had expected revenue of $10.29 billion.

GME.NY 11.24%
GameStop Corp – At the beginning of the month we learned GME was planning a “at-the-market” stock offering which at the time was viewed as a way to capitalize on its recent head-turning, WallStreetBets led history making rally. GME announced aftermarket yesterday it had sold 3.5 million additional shares, raising $551 million, proceeds that will be used to speed up the company’s e-commerce transformation.

UPS.NY 7.10%
United Parcel Service Inc – Shares were up nearly 8% premarket the parcel delivery company posted a 27% rise in Q1 rev beating analyst est., helped by a surge in online purchases during the COVID-19 pandemic. Adj EPS was $2.77 per share in Q1, beating est of $1.72 per share. UPS said revenue in its U.S. domestic unit rose 22.3%, led by growth from small- and medium-sized businesses.

GE.NY -2.36%
General Electric – Reported a 20% decline in quarterly profit, hit by a slump in demand for aircraft engines as airlines struggle to recover from a pandemic-led collapse in travel. The company, however, reaffirmed its full-year free cash flow and earnings per share outlook. On an adjusted basis, GE’s industrial profit fell to $828 million, from $1.03 billion a year earlier. Excluding items, GE earned 3 cents per share in the quarter, compared with 2 cents per share a year earlier. Revenue fell 12% to $17.12 billion.

MNMD.NQ 21.32%
Mind Medicine Inc – Set to make its debut on the Nasdaq this morning trading under the symbol “MNMD”. The New York-based company will become the second psychedelic company ever to go public on a major American exchange. Shroom drug developer COMPASS Pathways CMPS was the first listing coming to market only six months ago, while another “drug growth platform,” called Atai Life Sciences ATAI, filed to go public last week.

MVIS.NQ 7.68%
MicroVision Inc – Continues its impressive, WSB led run up another 10% premarket, the recent “meme” stock leader jumped 47% on Monday while other Reddit favorites also rallied, suggesting that interest in so-called meme stocks remains strong after a wild ride this year. MicroVision, which develops laser scanning technology for automotive lidar sensors and augmented reality, was the most mentioned stock on Reddit’s popular WallStreetBets forum again on Monday, according to sentiment tracker SwaggyStocks.

SNAP.NY -1.73%
Snap Inc – Announced plans to offer $1 billion of convertible debt due 2027 in a private placement aftermarket yesterday, with the proceeds set to be used for general corporate purposes. Notes will accrue interest payable semiannually in arrears. The company said it also plans to give initial purchasers of the notes option to purchase up to additional $150 mln of notes.

CCIV.NY 2.22%
Churchill Capital IV Corp – Up another 3% premarket after yesterday’s rally that was fueled by rumors of a possible arrangement with Apple. An interview with Lucid Motors CEO was circulated online where the company didn’t immediately deny the possibly of discussions but also did not comment further on the topic.

OCGN.NQ -5.70%
Ocugen Inc – Trading lower in the premarket after three straight up days, the move was kicked off by further positive data on its covid 19 vaccine which it teamed up with India-based Bharat Biotech to develop and bring to the American market. Ocugen will receive nearly half of all U.S. profits from Covaxin without having to make an investment in partner company Bharat Biotech.

RIBT.NQ 20.43%
RiceBran Technologies – Micro-cap food processing company updated its current quarter quidance to the upside, saying it expects to report a 6.8% decrease in revenue to $7.766 million from $8.33 million a year ago, according to the estimate from one analyst, the decline would be smaller than first expected.

ALDX.NQ 23.85%
Aldeyra Therapeutics Inc – The company’s recent conjunctivitis treatment trial meets late-stage study main goals.

Leave a Reply

Your email address will not be published.